BioAlliance Pharma Announces the Grant of Its Main Patent on The Lauriad Technology in Europe

The patent has been validated in the main European countries and the opposition period has now expired

26-Aug-2008 - France

BioAlliance Pharma SA announced the grant of its main patent on the Lauriad® technology in Europe. The patent describes and protects a muco-adhesive tablet for various applications in the field of opportunistic infections associated with AIDS and cancer. It has been validated in the main European countries and the opposition period has now expired.

"The grant of this patent acknowledges the true innovation behind the Lauriad® muco-adhesive technology", stated Dominique Costantini, President and CEO of BioAlliance Pharma. "It reinforces our positioning in the target markets for the Lauriad® technology: oropharyngeal candidiasis, labial herpes and chronic pain".

BioAlliance Pharma's patent portfolio now encompasses 25 published patent families (comprising 196 patent applications and granted patents) covering innovative technologies or products in the fields of opportunistic infections, cancer and AIDS. More than half the portfolio is made up of granted patents.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances